Chondramide B

Drug Profile

Chondramide B

Latest Information Update: 20 Mar 2002

Price : $50

At a glance

  • Originator GBF
  • Class Cytostatic antibiotics; Depsipeptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Mar 2002 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 28 Oct 1997 No-Development-Reported for Cancer in Germany (Unknown route)
  • 08 Oct 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top